The BioStar OIA CHLAYMDIA test delivers 100% specificity and 100% PPV with test results in 19 minutes. With as many as one-fourth of patients not returning for follow-up, this assay provides a test & treat solution which can contribute to detection and treatment while reducing overall costs of chlamydia infections in women.

Easy to Use

• No instrumentation.
• All components included in kit.
• Minimal hands-on time.
• Test may be performed in discrete or batch format.
• Built-in controls and permanent test results provide assurance that test is performed properly.

Further Benefits of the BioStar OIA CHLAMYDIA test

• "OIA presented comparable diagnostic efficiency to single pass culture,"¹ 83.6% sensitivity (95% confidence interval 73.9% - 93.4%).²
• Results now available in 19 minutes. Therefore, treatment decisions can be made during the same office visit.

When it Comes to Chlamydia,
Timing is Everything

As many as one-fourth of patients diagnosed with Chlamydia never return for treatment.³

Treatment delays of as little as three days from the onset of symptoms can result in infertility and/or ectopic pregnancies.⁴

Routine screening for Chlamydia can lead to a reduction in the incidence of PID by roughly 56%.⁵

Research shows the average time between testing and treatment can be as long as 14 days.³

The 19-minute, in-office procedure of the OIA CHLAMYDIA product enables the physician to make the treatment decision during the same visit.

About Chlamydia

There are an estimated 89 million chlamydial infections worldwide.⁶ The true incidence of infection may be even greater since the disease is frequently asymptomatic.⁷

Up to two-thirds of infected women may be asymptomatic,⁷ often resulting in total lack of treatment.

Chlamydia has been isolated from up to 50% of women seeking care for symptoms of pelvic inflammatory disease (PID), a leading cause of infertility.⁸

Bibliography & References

• Gift, T.; Pate, M.; Hook, E.; Kassler, W. The rapid test paradox: when fewer cases detected lead to more cases treated. Sexually Transmitted Diseases. 26, 4:232-240
• Howell, R.; Quinn, T.; Brathwaite, W.; Gaydos, C. Screening women for Chlamydia Trachomatis in family planning clinics. Sexually Transmitted Diseases. 25, 2:108-117
• Pate, M.; Dixon, Paula.; Hardy, Kim.; Crosby, M., Hook, E.W. Evaluation of the BioStar OIA CHLAMYDIA assay with specimens from women attending a sexulally transmiited disease clinic. J Clin Microbiol. 36, 8:2183-2186
• Schachter, J. We must be realistic in evaluating rapid diagnostic tests. Sexually Transmitted Diseases. 26, 4:241-242
• Webb, K. Cost-effective screening for chlamydia trachomatis: are DNA amplification assays the answer? Sexually Transmitted Diseases. 25, 8:403-405

1. Wells, A., et al. Evaluation of a rapid antigen-detection assay, BioStar OIA CHLAMYDIA assay for C. trachomatis in an outpatient population, 1995. ICAAC Poster Presentation.
2. BioStar OIA CHLAMYDIA Package Insert.
3. Hook, Edward W II, MD, et al. Use of Cell Culture and Rapid Diagnostic Assay for Chlamydia.
4. Hillis, Susan D., PhD. et al. Delayed Care of Pelvic Inflammatory Disease as a Risk Factor for Impaired Fertility, American Journal of Obstetrics and Gynecology, 1993, vol. 168, p. 1503.
5. Scholas, D., et al. Prevention of Pelvic Inflammatory Disease by Screening for Cervical Chlamydia Infection, The New England Journal of Medicine, 1996, vol. 334, p. 1362.
6. World Health Organization Health Report 2000
7. Heath, Cathryn B., Heath, John M., Chlamydia trachomatis Infection Update. American Family Physician, 1995, vol. 52, p. 1455.
8. Recommendation for the Prevention and Management of Chlamydia trachomatis Infections, 1993. Centers for Disease Control and Prevention (CDC) MMWR, vol. 42, p. 1.